scholarly journals Effect of the enzyme replacement therapy on hypertrophic cardiomyopathy in an infant with the CRIM-negative infantile Pompe's disease

Author(s):  
Guy Vaksmann ◽  
Anne-Sophie Guemann ◽  
Karine Mention
2003 ◽  
Vol 27 (6) ◽  
pp. 743-751 ◽  
Author(s):  
L�on P. F. Winkel ◽  
Joep H. J. Kamphoven ◽  
Hannerieke J. M. P. Van Den Hout ◽  
Lies A. Severijnen ◽  
Pieter A. Van Doorn ◽  
...  

2004 ◽  
Vol 55 (4) ◽  
pp. 495-502 ◽  
Author(s):  
L�on P. F. Winkel ◽  
Johanna M. P. Van den Hout ◽  
Joep H. J. Kamphoven ◽  
Janus A. M. Disseldorp ◽  
Maaike Remmerswaal ◽  
...  

2011 ◽  
Vol 152 (39) ◽  
pp. 1569-1575
Author(s):  
Benjamin Bereznai ◽  
Anita Trauninger ◽  
Ilona György ◽  
Katalin Szakszon ◽  
Zsuzsanna Almássy ◽  
...  

Pompe’s disease is an autosomal recessive disease caused by deficiency of acid-alpha-glucosidase. Aims and Methods: Authors analyzed the phenotype of 11 Hungarian patients with Pompe’s disease and evaluated clinical parameters and response to enzyme replacement therapy during a long-term follow-up in 8 patients. Results: One patient with atypical infantile form presented with cardiomyopathy and a very slow progression of motor deficits; after 2 years of enzyme replacement therapy no disability was present at the age 6 years. Another patient was asymptomatic at the age of 2.5 years. The adult onset form was characterized by slight to prominent limb-girdle myopathy with an age of onset between 20 and 50 years. In 3 of such cases respiratory insufficiency was also present. Conclusions: Hungarian patients with Pompe’s disease presented with a wide phenotypic variability ranging from atypical early childhood form with slowly progressive course to late-onset limb-girdle myopathy with variable courses. Enzyme replacement therapy resulted in significant improvement in motor and respiratory functions in most of the patients. Orv. Hetil., 2011, 152, 1569–1575.


Sign in / Sign up

Export Citation Format

Share Document